Rocket Pharmaceuticals is trading 5.08% lower at $2.24, with biotech and broader-market weakness the likeliest context for the decline; no clear company-specific catalyst has been identified for October 16, 2026. - XBI is down 2.06%, while major U.S. indexes are lower. - The company announced an October 15 conference appearance, but available coverage does not link it to today’s decline.